Understand the source comparison
SS-31 Per Day Daily Dose: Research vs Clinical Context
Rodent Research (Published) 1–5mg/kg/day (0.25–1.25mg for 250g rat) Subcutaneous daily 400–600ng/mL peak Extensive preclinical data Gold standard for mechanism studies; not directly translatable to humans without allometric correction Allometric Human Equivale
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rodent Research (Published)
- 1–5mg/kg/day (0.25–1.25mg for 250g rat)
- Subcutaneous daily
- 400–600ng/mL peak
- Extensive preclinical data
- Gold standard for mechanism studies; not directly translatable to humans without allometric correction
- Allometric Human Equivalent
- 0.16–0.81mg/kg/day (11–57mg for 70kg)
- Estimated 60–150ng/mL
- Calculated extrapolation
- Theoretical starting point for human protocols; not clinically validated
- MMPOWER-3 Clinical Trial
- 40mg/day fixed dose (0.57mg/kg for 70kg)
- 80–120ng/mL steady-state
- Phase 2 clinical data
- Safe for chronic use but below threshold for robust efficacy in myopathy trials
- TACTIC-HCM Acute Dosing
- 0.25mg/kg single dose (17.5mg for 70kg)
- IV bolus infusion
- 150–200ng/mL peak (transient)
- Produces measurable cardiac effects acutely; not suitable for chronic metabolic support
- High-Dose IV (EMBRACE Trial)
- 4mg/kg single dose (280mg for 70kg)
- Estimated >1000ng/mL peak
- Tolerated in acute MI setting but no chronic safety data; impractical for daily use
- Investigational Chronic High-Dose
- 80–120mg/day (1.1–1.7mg/kg for 70kg)
- Subcutaneous BID
- Estimated 150–250ng/mL
- No published human data
- Hypothetical dose to achieve sustained therapeutic plasma levels based on PK modeling